Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Pharmacol Res. 2020 May 11;158:104847. doi: 10.1016/j.phrs.2020.104847

Figure 2.

Figure 2.

Surface plasmon resonance (SPR) validation of the PS inhibitory effects for the PCSK9-LDLR interaction. (A) SPR sensogram of PS different concentrations (150 μM, 100 μM, 75 μM, 50 μM, 40 μM, and 10 μM) binding to the immobilized PCSK9 in dose dependent manner. (B) SPR sensogram for competitive assay binding of PS and PCSK9 with immobilized LDLR at injection of PS with different doses (200 μM, 100 μM, 75 μM, 50 μM, 20 μM, and 10 μM) in the presence of 200 nM PCSK9. Berberine 100 μM used as a negative control.